Cantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)

Shattuck Labs, Inc. (NASDAQ:STTK) is one of the best performing small cap stocks so far in 2026. Cantor Fitzgerald initiated coverage of Shattuck Labs, Inc. (NASDAQ:STTK) with an Overweight rating on April 27, telling investors in a research note that the stock’s more than 800% rise over the last 12 months points towards enthusiasm for its DR3 and TL1A programs. It added that investors are betting on differentiated efficacy and upcoming early-phase data that could de-risk key drug attributes, and that continued clinical readouts across several autoimmune indications and interest in combination or bispecific approaches could further support upside.

Shattuck Labs, Inc. (NASDAQ:STTK) also received a rating update from H.C. Wainwright on April 20. The firm lifted the price target on the stock to $18 from $6, reiterating a Buy rating on the shares. The firm raised its projected SL-325 probability of success to 15% from 10% based on projections for a broad positive upcoming dataset.

Shattuck Labs, Inc. (NASDAQ:STTK) is a biotechnology company involved in the research and development of potential treatments for inflammatory and immune-mediated diseases. The company’s focus is on the development of a potential first-in-class antibody to treat inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases.

While we acknowledge the risk and potential of STTK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than STTK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.